Kazia Therapeutics Ltd ADR
KZIANASDAQHealthcareBiotechnology
Latest quote
$13.20
−$0.205 · -1.53%
After-hours
$13.20
$0.00 · 0.00%
Aug 24, 4:10 PM ET
KZIA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
36
Expensive
Momentum
69
Gaining
Sentiment
67
Bullish
Risk resilience
35
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteKazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- AU
- CEO
- John Friend
- Listed since
- Jan 6, 1999
- Employees
- 6
Market position
Day range
Current $13.20
52-week range
Current $13.20
- Open
- $13.36
- Previous close
- $13.405
- Volume
- 0
- 0× average
- Average volume
- 214.93K
- Average daily volume
- Market cap
- 21.38M USD
- Beta
- 2.17
- Market reference 1
- 50-day average
- $13.4182
- -1.63% below average
- 200-day average
- $10.2162
- +29.21% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 6.49M AUD
- P/E (TTM)
- -1.78×
- P/B (TTM)
- 1.24×
- P/S (TTM)
- 1,516.86×
- EV / EBITDA
- -0.49×
- Earnings yield
- -198.39%
- Free cash flow yield
- -127.25%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 100.00%
- Operating margin
- -92086.45%
- Net margin
- -113004.58%
- Return on equity
- 249.39%
- Return on assets
- -341.56%
- Return on invested capital
- 172.61%
Financial health
- Debt / equity
- 0×
- Current ratio
- 0.35×
- Altman Z-score
- -3.51
- Piotroski F-score
- 3 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (AUD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 42K AUD | 2.31M AUD | 555 AUD | 10K AUD | 15.18M AUD |
| Gross profit | 42K AUD | 2.31M AUD | 555 AUD | 10K AUD | 15.18M AUD |
| Research and development | 7.33M AUD | 17.38M AUD | 15.56M AUD | 20.17M AUD | 14.54M AUD |
| Selling, general, and administrative | 8.72M AUD | 13.56M AUD | 8.58M AUD | 5.24M AUD | 7.02M AUD |
| Operating expenses | 14.26M AUD | 30.77M AUD | 24.12M AUD | 25.41M AUD | 21.56M AUD |
| Interest income | 72K AUD | 12K AUD | 22.84K AUD | 2.09K AUD | 42.24K AUD |
| Interest expense | — | — | — | 2.09K AUD | — |
| Depreciation and amortization | 934K AUD | 1.87M AUD | 1.87M AUD | 1.87M AUD | 1.27M AUD |
| Operating income | −14.22M AUD | −28.46M AUD | −24.12M AUD | −25.4M AUD | −6.38M AUD |
| Net income | −20.7M AUD | −26.78M AUD | −20.47M AUD | −25.01M AUD | −8.42M AUD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 25%
- 2 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -2009.08%
- 8 comparable reports
- Latest EPS result
- -0.58
- Estimate -0.01 · Miss by 8205.16%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$30.00
127.27% upsideRating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
KZIA news
KZIA peers
ETFs holding KZIA
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research KZIAresearch.disclaimer